New drug combo aims to shrink prostate tumors before surgery
NCT ID NCT06631521
First seen Feb 05, 2026 · Last updated May 14, 2026 · Updated 16 times
Summary
This early-phase trial tests whether giving two drugs (darolutamide and relugolix) before prostate cancer surgery is safe and helps shrink tumors. It involves 30 men with high-risk prostate cancer. The main goal is to see how many patients complete the treatment without serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER (ADENOCARCINOMA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AdventHealth Orlando
RECRUITINGOrlando, Florida, 32803, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.